OneSource Specialty Pharma share price today

OneSource Specialty Pharma Ltd's share price was ₹1,583.60 at the close on 4 November 2026. It has been falling for 11 weeks. That is 0.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,114 and ₹1,838, and at that close it sat 65% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today OneSource Specialty Pharma Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 1 year the share price moved −7% while the NIFTY 500 moved +3%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, started beating the market again after 13 weeks behind it and highest quarterly revenue in 13 quarters.

1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row

   From 12.6% to 24.2% of the company by the September 2026 quarter.

2. Started beating the market again after 13 weeks behind it

3. Highest quarterly revenue in 13 quarters

   Revenue of ₹516 crore in the September 2026 quarter is the highest of the last 13 quarters.

   Why: The September quarter was the best in 13 quarters because the second cartridge line started making commercial batches in September, adding more production of sterile medicines.

   Next results: check whether the third cartridge line passes site checks and starts making commercial batches in the expected window.

   From the earnings call on 27 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), OneSource Specialty Pharma reported revenue of ₹516 crore, up 37.2% from ₹376 crore a year earlier, and a profit of ₹57.0 crore, up 470.0% from ₹10.0 crore.

OneSource Specialty Pharma results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

OneSource Specialty Pharma's management discussed these results on a call held on 27 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

OneSource Specialty Pharma closed at ₹1,583.60 on 4 November 2026, down 10.9% from ₹1,777.60 a year earlier (7 November 2025). Its highest weekly close since January 2025 was ₹2,194.00 on 27 June 2025.

OneSource Specialty Pharma share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

100 weekly closes from 24 January 2025 to 4 November 2026.

4 Nov 2026: OneSource Specialty Pharma closed at ₹1,583.60, up 1.3% on the week and up 5.0% on the month. 27 Oct 2026: OneSource Specialty Pharma held its results call for July to September 2026. Management guided: FY28 revenue USD 400M with reported operating profit USD 160M reaffirmed.

Earlier

• Results for July to September 2026: Revenue up 37.2% and profit up 470.0% on a year earlier.

OneSource Specialty Pharma has paid no dividend on the NSE since its first NSE close in our records (24 January 2025), the start of the period we checked.

No. OneSource Specialty Pharma Ltd paid out 0% of its profit as dividends in each of its last 6 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 27 October 2026, OneSource Specialty Pharma's management guided: FY28 revenue USD 400M with reported operating profit USD 160M reaffirmed.

“Every one of our lines is backed by full end-to-end capabilities, including not only cartridge filling but also assembly, labeling, packaging, and so on, including cold chain, all under one roof. - Neeraj”CEO and MD, on the call for July to September 2026

What management guided

• H2FY27 stronger than H1FY27 on launches and commercial ramp.
• All three DDC lines operational and available for FY28; Line 3 Q4 effort with possible early FY28 start.
• ETR to stay at current level through October to December 2027 on brought-forward losses.
• Debt around 1.5x operating profit with ROCE in high-20s by end FY28.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 27 October 2026.

When OneSource Specialty Pharma reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Line 3 progress from site qualification to commercial batches against guided window - check for further slip language.

OneSource Specialty Pharma is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

OneSource Specialty Pharma Ltd earned ₹57.0 Cr of net profit in the Sep 2026 quarter, +470.0% on the same quarter a year earlier. The full FY26 year was a loss of ₹74.0 Cr. That is 11.0% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr. 6 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

OneSource Specialty Pharma Ltd reported ₹516 Cr of revenue in the Sep 2026 quarter, +37.2% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 5 years it has grown 132.3% a year on average. The last full year, FY26, came in at ₹1,422 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,683 Cr.

FY26 revenue was ₹1,422 Cr, −1.6% on the year before.

Recent pace: the last four quarters grew +12.2% on average, against 132.3% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +49.3% a year over the last 8 quarters (rolling over).

OneSource Specialty Pharma Ltd's operating margin was 32.0% in the Sep 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Across 6 years it has been between −415.0% and 32.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.3 percentage points on the year while gross margin changed +1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

OneSource Specialty Pharma Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 it brought in ₹9.0 Cr of operating cash against −₹74.0 Cr of profit. After ₹489 Cr of spending on assets, free cash was −₹480 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

OneSource Specialty Pharma Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹1,422 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹5,480 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Averaged over those years that is 128.5% of FY26 revenue a year.

Spending on assets: ₹5,480 Cr over the last 3 years, against ₹629 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹529 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

OneSource Specialty Pharma Ltd's P/E is 1,587.7×, about the highest it has ever been. Its usual P/E (the middle reading) is 240.5×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

OneSource Specialty Pharma Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

OneSource Specialty Pharma Ltd earned a ROCE of 1% in FY26. That is up from a low of −12% in FY23. Its return on capital used (ROIC) is 11.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a −5.2% net margin and 0.17× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a −5.2% net margin × 0.17× asset turnover × 1.42× leverage (assets divided by equity) ≈ −1.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 0.7% − 12.0% = −11.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

OneSource Specialty Pharma Ltd has total debt of ₹1,755 Cr against shareholder equity of ₹5,921 Cr as of Sep 2026, so its debt is 0.30× its equity, which is very little. Year by year, that ratio went from 1.44 in FY24 to 0.26 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in OneSource Specialty Pharma Ltd by 11.6 percentage points over 7 quarters, the biggest change among its owners. Domestic institutions now own 24.2% of the company. Promoters moved −7.3 points over the same period, to 30.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +11.6 points over 7 quarters, to 24.2%; Promoters: −7.3 points over 7 quarters, to 30.5%; Foreign institutions: +2.0 points over 7 quarters, to 19.4%.

Why the owners changed: domestic institutions drove it (+11.6 points), with the other side taken by promoters (−7.3 points). They raised their stake step by step.

For OneSource Specialty Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

29.2 out of 100, rank 21 of 24 in Pharma - API & CRAMS, with 83% of the evidence available.

OneSource Specialty Pharma Ltd scores 29.2 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 21. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 12.4 + 4.1 + 8.5 + 4.2 = 29.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

OneSource Specialty Pharma ranks 21 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 29.2 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - API & CRAMS, all 24 compared on one page.

OneSource Specialty Pharma is the 11th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Neuland Laboratories, Granules India and Shilpa Medicare. Just below it: Cohance Lifesciences, Syngene International and Jubilant Pharmova.

Pharma - API & CRAMS companies close in size

8. Neuland Laboratories Ltd ₹25,275 crore
9. Granules India Ltd ₹22,907 crore
10. Shilpa Medicare Ltd ₹18,690 crore
11. OneSource Specialty Pharma Ltd ₹17,924 crore
12. Cohance Lifesciences Ltd ₹16,999 crore
13. Syngene International Ltd ₹16,256 crore
14. Jubilant Pharmova Ltd ₹14,716 crore

All 24 Pharma - API & CRAMS companies, largest first

Companies close in size in other industries

383. Castrol India Ltd ₹18,596 crore · Lubricants
384. Aadhar Housing Finance Ltd ₹18,417 crore · Finance - Housing
385. OneSource Specialty Pharma Ltd ₹17,924 crore
386. EIH Ltd ₹17,907 crore · Hotels
387. Pine Labs Ltd ₹17,697 crore · E-Commerce - Platform - Utility

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.